Literature DB >> 35462730

Update on the Use of Vedolizumab in Patients With Crohn's Disease.

Brian Bressler1.   

Abstract

Entities:  

Year:  2021        PMID： 35462730      PMCID： PMC9021172     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

1.  Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.

Authors:  Brian G Feagan; Karen Lasch; Trevor Lissoos; Charlie Cao; Abigail M Wojtowicz; Javaria Mona Khalid; Jean-Frédéric Colombel
Journal:  Clin Gastroenterol Hepatol       Date:  2018-05-29       Impact factor: 11.382

2.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.

Authors:  Bruce E Sands; Brian G Feagan; Paul Rutgeerts; Jean-Frédéric Colombel; William J Sandborn; Richmond Sy; Geert D'Haens; Shomron Ben-Horin; Jing Xu; Maria Rosario; Irving Fox; Asit Parikh; Catherine Milch; Stephen Hanauer
Journal:  Gastroenterology       Date:  2014-05-21       Impact factor: 22.682

3.  Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.

Authors:  Silvio Danese; William J Sandborn; Jean-Frédéric Colombel; Séverine Vermeire; Sarah C Glover; Jordi Rimola; Jenifer Siegelman; Stephen Jones; Jeffrey D Bornstein; Brian G Feagan
Journal:  Gastroenterology       Date:  2019-07-04       Impact factor: 22.682

4.  Vedolizumab as induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

5.  Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.

Authors:  Brian Bressler; Andres Yarur; Mark S Silverberg; Marielle Bassel; Emanuelle Bellaguarda; Chris Fourment; Anthie Gatopoulou; Pantelis Karatzas; Uri Kopylov; George Michalopoulos; Spyridon Michopoulos; Udayakumar Navaneethan; David T Rubin; Jesse Siffledeen; Andrew Singh; Konstantinos Soufleris; Dara Stein; Dirk Demuth; Gerassimos J Mantzaris
Journal:  J Crohns Colitis       Date:  2021-10-07       Impact factor: 9.071

6.  Long-term safety of vedolizumab for inflammatory bowel disease.

Authors:  Edward V Loftus; Brian G Feagan; Remo Panaccione; Jean-Frédéric Colombel; William J Sandborn; Bruce E Sands; Silvio Danese; Geert D'Haens; David T Rubin; Ira Shafran; Andrejus Parfionovas; Raquel Rogers; Richard A Lirio; Séverine Vermeire
Journal:  Aliment Pharmacol Ther       Date:  2020-09-02       Impact factor: 8.171
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.